Diplomat Pharmacy Inc (NYSE:DPLO) has been given a consensus recommendation of “Hold” by the sixteen brokerages that are currently covering the firm, Marketbeat Ratings reports. Two investment analysts have rated the stock with a sell rating, ten have assigned a hold rating, two have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among brokers that have covered the stock in the last year is $10.25.
A number of equities analysts have weighed in on the company. Guggenheim started coverage on Diplomat Pharmacy in a research note on Wednesday, April 17th. They issued a “neutral” rating and a $6.00 target price on the stock. Zacks Investment Research lowered Diplomat Pharmacy from a “buy” rating to a “hold” rating in a research report on Tuesday, July 16th. ValuEngine upgraded Diplomat Pharmacy from a “buy” rating to a “strong-buy” rating in a research report on Thursday, August 1st. Finally, Credit Suisse Group reduced their price objective on Diplomat Pharmacy from $8.00 to $6.00 and set a “neutral” rating on the stock in a research report on Monday, April 29th.
NYSE DPLO traded up $0.40 during trading on Friday, reaching $5.72. The company’s stock had a trading volume of 2,792,765 shares, compared to its average volume of 603,767. The company has a market capitalization of $382.53 million, a PE ratio of 28.60 and a beta of 1.06. The company has a debt-to-equity ratio of 1.00, a current ratio of 1.00 and a quick ratio of 0.66. The stock has a fifty day moving average of $5.57. Diplomat Pharmacy has a one year low of $4.17 and a one year high of $21.48.
Diplomat Pharmacy (NYSE:DPLO) last announced its earnings results on Friday, August 9th. The company reported ($0.21) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.20) by ($0.01). The business had revenue of $1.29 billion during the quarter, compared to the consensus estimate of $1.23 billion. Diplomat Pharmacy had a positive return on equity of 1.38% and a negative net margin of 5.85%. Diplomat Pharmacy’s revenue was down 9.1% compared to the same quarter last year. During the same quarter in the prior year, the company earned ($0.05) earnings per share. As a group, equities analysts forecast that Diplomat Pharmacy will post -0.55 earnings per share for the current year.
Several institutional investors have recently made changes to their positions in DPLO. KBC Group NV bought a new position in shares of Diplomat Pharmacy during the 2nd quarter valued at about $46,000. Quantamental Technologies LLC purchased a new stake in Diplomat Pharmacy during the 1st quarter valued at about $63,000. Bank of Montreal Can boosted its holdings in Diplomat Pharmacy by 138.4% during the 2nd quarter. Bank of Montreal Can now owns 11,444 shares of the company’s stock valued at $70,000 after acquiring an additional 6,644 shares during the period. BNP Paribas Arbitrage SA boosted its holdings in Diplomat Pharmacy by 446.9% during the 1st quarter. BNP Paribas Arbitrage SA now owns 13,104 shares of the company’s stock valued at $76,000 after acquiring an additional 10,708 shares during the period. Finally, Acorn Wealth Advisors LLC purchased a new stake in Diplomat Pharmacy during the 1st quarter valued at about $82,000. Hedge funds and other institutional investors own 79.40% of the company’s stock.
Diplomat Pharmacy Company Profile
Diplomat Pharmacy, Inc operates as an independent specialty pharmacy in the United States. The company operates through Specialty and PBM (pharmacy benefit management) segment. It provides specialty infusion pharmacy, patient care coordination, clinical, compliance and persistency program, patient financial assistance, specialty pharmacy training, benefits investigation, prior authorization, risk evaluation and medication strategy, retail specialty, and hub services, as well as clinical and administrative support services to hospitals and health systems.
Recommended Story: How are the companies in the S&P 500 selected?
Receive News & Ratings for Diplomat Pharmacy Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diplomat Pharmacy and related companies with MarketBeat.com's FREE daily email newsletter.